Is AMRN or RNTX more profitable?

Rein Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Rein Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Amarin -15.51% -2.99% -2.07% Rein Therapeutics N/A -510.35% -68.14%

Is ABEO or RNTX more profitable?

Abeona Therapeutics' return on equity of -53.98% beat Rein Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -53.98% -38.52% Rein Therapeutics N/A -510.35% -68.14%

Rein Therapeutics (RNTX) Competitors

$0.97 +0.06 (+7.16%)

As of 04:00 PM Eastern

Compare

RNTX vs. AMRN, SLN, ABEO, LYEL, and FENC

Should you buy Rein Therapeutics stock or one of its competitors? MarketBeat compares Rein Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rein Therapeutics include Amarin (AMRN), Silence Therapeutics (SLN), Abeona Therapeutics (ABEO), Lyell Immunopharma (LYEL), and Adherex Technologies (FENC). These companies are all part of the "pharmaceutical products" industry.

How does Rein Therapeutics compare to Amarin?

Amarin (NASDAQ:AMRN) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Rein Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Rein Therapeutics	N/A	-510.35%	-68.14%

Amarin currently has a consensus price target of $12.00, suggesting a potential downside of 24.86%. Rein Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 622.69%. Given Rein Therapeutics' higher probable upside, analysts plainly believe Rein Therapeutics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Amarin has higher revenue and earnings than Rein Therapeutics. Amarin is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.57	-$38.80M	-$0.65	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A

In the previous week, Amarin had 16 more articles in the media than Rein Therapeutics. MarketBeat recorded 16 mentions for Amarin and 0 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.00 beat Amarin's score of 0.56 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Amarin	Positive
Rein Therapeutics	Positive

Amarin has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

22.3% of Amarin shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 1.5% of Rein Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Amarin beats Rein Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Rein Therapeutics compare to Silence Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Rein Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -105.34% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	-510.35%	-68.14%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

Rein Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

Rein Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 622.69%. Silence Therapeutics has a consensus price target of $55.00, indicating a potential upside of 656.53%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Rein Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Silence Therapeutics had 4 more articles in the media than Rein Therapeutics. MarketBeat recorded 4 mentions for Silence Therapeutics and 0 mentions for Rein Therapeutics. Silence Therapeutics' average media sentiment score of 1.37 beat Rein Therapeutics' score of 1.00 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Rein Therapeutics	Positive
Silence Therapeutics	Positive

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 1.5% of Rein Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Rein Therapeutics has higher earnings, but lower revenue than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A
Silence Therapeutics	$560K	613.28	-$88.61M	-$1.59	N/A

Summary

Silence Therapeutics beats Rein Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Rein Therapeutics compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Abeona Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market.

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Rein Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Rein Therapeutics' average media sentiment score of 1.00 beat Abeona Therapeutics' score of -0.05 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Abeona Therapeutics	Neutral
Rein Therapeutics	Positive

Abeona Therapeutics presently has a consensus target price of $19.00, indicating a potential upside of 232.17%. Rein Therapeutics has a consensus target price of $7.00, indicating a potential upside of 622.69%. Given Rein Therapeutics' higher probable upside, analysts clearly believe Rein Therapeutics is more favorable than Abeona Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Abeona Therapeutics' return on equity of -53.98% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Rein Therapeutics	N/A	-510.35%	-68.14%

Abeona Therapeutics has higher revenue and earnings than Rein Therapeutics. Rein Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	56.01	$71.18M	$0.97	5.90
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A

Summary

Abeona Therapeutics beats Rein Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Rein Therapeutics compare to Lyell Immunopharma?

Lyell Immunopharma (NASDAQ:LYEL) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Rein Therapeutics has lower revenue, but higher earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	7,366.45	-$274.45M	-$13.80	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A

Lyell Immunopharma has a beta of -0.09, meaning that its share price is 109% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

In the previous week, Rein Therapeutics' average media sentiment score of 1.00 beat Lyell Immunopharma's score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lyell Immunopharma	Neutral
Rein Therapeutics	Positive

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 1.5% of Rein Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lyell Immunopharma presently has a consensus target price of $43.00, suggesting a potential upside of 240.46%. Rein Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 622.69%. Given Rein Therapeutics' higher probable upside, analysts clearly believe Rein Therapeutics is more favorable than Lyell Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Rein Therapeutics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Lyell Immunopharma's return on equity of -85.71% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%
Rein Therapeutics	N/A	-510.35%	-68.14%

Summary

Rein Therapeutics beats Lyell Immunopharma on 8 of the 15 factors compared between the two stocks.

How does Rein Therapeutics compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Adherex Technologies has higher revenue and earnings than Rein Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	8.05	-$9.74M	-$0.29	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A

Adherex Technologies currently has a consensus target price of $15.40, indicating a potential upside of 49.51%. Rein Therapeutics has a consensus target price of $7.00, indicating a potential upside of 622.69%. Given Rein Therapeutics' higher probable upside, analysts clearly believe Rein Therapeutics is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Rein Therapeutics' average media sentiment score of 1.00 beat Adherex Technologies' score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Adherex Technologies	Neutral
Rein Therapeutics	Positive

Adherex Technologies has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

Rein Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-17.12%	-43.87%	-11.35%
Rein Therapeutics	N/A	-510.35%	-68.14%

55.5% of Adherex Technologies shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by insiders. Comparatively, 1.5% of Rein Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Adherex Technologies beats Rein Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Rein Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNTX vs. The Competition

Export

Metric	Rein Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$77.32M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-0.51	19.75	24.92	23.97
Price / Sales	N/A	329.42	528.81	109.59
Price / Cash	15.81	128.56	44.82	54.51
Price / Book	-0.91	8.29	10.79	6.50
Net Income	-$49.87M	$23.85M	$3.56B	$336.88M
7 Day Performance	2.50%	5.21%	1.67%	-0.22%
1 Month Performance	-5.96%	2.19%	0.43%	0.77%
1 Year Performance	-35.43%	60.99%	32.84%	31.57%

Rein Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNTX Rein Therapeutics	4.0621 of 5 stars	$0.97 +7.2%	$7.00 +622.7%	-41.3%	$77.32M	N/A	N/A	9	Positive News
AMRN Amarin	1.1752 of 5 stars	$15.24 flat	$12.00 -21.3%	+26.1%	$319.58M	$213.65M	N/A	360
SLN Silence Therapeutics	2.9987 of 5 stars	$6.69 flat	$55.00 +722.1%	+26.6%	$316.04M	$560K	N/A	100	Positive News
ABEO Abeona Therapeutics	2.8479 of 5 stars	$5.53 flat	$19.00 +243.6%	-2.4%	$315.16M	$5.82M	5.70	90
LYEL Lyell Immunopharma	2.3183 of 5 stars	$13.50 flat	$43.00 +218.5%	+37.7%	$315.01M	$31K	N/A	270

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNTX) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rein Therapeutics (RNTX) Competitors

RNTX vs. AMRN, SLN, ABEO, LYEL, and FENC

How does Rein Therapeutics compare to Amarin?

Summary

How does Rein Therapeutics compare to Silence Therapeutics?

Summary

How does Rein Therapeutics compare to Abeona Therapeutics?

Summary

How does Rein Therapeutics compare to Lyell Immunopharma?

Summary

How does Rein Therapeutics compare to Adherex Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX vs. The Competition

Rein Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rein Therapeutics (RNTX) Competitors

RNTX vs. AMRN, SLN, ABEO, LYEL, and FENC

How does Rein Therapeutics compare to Amarin?

Is AMRN or RNTX more profitable?

Do analysts recommend AMRN or RNTX?

Which has stronger earnings & valuation, AMRN or RNTX?

Does the media prefer AMRN or RNTX?

Which has more volatility and risk, AMRN or RNTX?

Do institutionals & insiders have more ownership in AMRN or RNTX?

Summary

How does Rein Therapeutics compare to Silence Therapeutics?

Is RNTX or SLN more profitable?

Which has more risk and volatility, RNTX or SLN?

Do analysts rate RNTX or SLN?

Does the media favor RNTX or SLN?

Do insiders & institutionals believe in RNTX or SLN?

Which has stronger earnings & valuation, RNTX or SLN?

Summary

How does Rein Therapeutics compare to Abeona Therapeutics?

Which has more risk and volatility, ABEO or RNTX?

Do institutionals & insiders believe in ABEO or RNTX?

Does the media refer more to ABEO or RNTX?

Do analysts rate ABEO or RNTX?

Is ABEO or RNTX more profitable?

Which has higher earnings & valuation, ABEO or RNTX?

Summary

How does Rein Therapeutics compare to Lyell Immunopharma?

Which has higher valuation and earnings, LYEL or RNTX?

Which has more volatility & risk, LYEL or RNTX?

Does the media refer more to LYEL or RNTX?

Do institutionals and insiders believe in LYEL or RNTX?

Do analysts prefer LYEL or RNTX?

Is LYEL or RNTX more profitable?

Summary

How does Rein Therapeutics compare to Adherex Technologies?

Which has stronger valuation & earnings, FENC or RNTX?

Do analysts recommend FENC or RNTX?

Does the media refer more to FENC or RNTX?

Which has more volatility and risk, FENC or RNTX?

Is FENC or RNTX more profitable?

Do institutionals and insiders have more ownership in FENC or RNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX vs. The Competition

Rein Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools